PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
121.05%
Net income growth above 1.5x TRAW's 10.34%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
473.10%
Some D&A expansion while TRAW is negative at -30.50%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
20.60%
Deferred tax of 20.60% while TRAW is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-20.60%
Both cut yoy SBC, with TRAW at -1.13%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
534.15%
Well above TRAW's 22.39% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.02%
Lower AP growth vs. TRAW's 522.79%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
107.35%
Some yoy usage while TRAW is negative at -124.82%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-145.76%
Negative yoy while TRAW is 95.24%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-3.22%
Negative yoy CFO while TRAW is 13.27%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-7359.68%
Both yoy lines negative, with TRAW at -108.33%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth of 100.00% while TRAW is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
-7359.68%
We reduce yoy invests while TRAW stands at 49.58%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
37.62%
Debt repayment growth of 37.62% while TRAW is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
299.00%
Issuance growth of 299.00% while TRAW is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.